Studies have [48–51] demonstrated the anti-leukemic effects of ASB2 and RARA, suggesting that the FTO/ASB2 or RARA axis likely plays a critical role in the pathogenesis of AML [52]. This evidence concerns the gene FTO and acute myeloid leukemia.